Delivery Order SPE2DB22D2007-SPE2DB25FJ4PJ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of IMBRUVICA 140 mg capsules (90-count units) with a ceiling value of $16,233.74. This competitively awarded, firm fixed-price contract has an ultimate completion date of September 10, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $16,233.74 to AmerisourceBergen Drug Corp for the supply of Imbruvica 140 mg capsules (90-count units) on September 3, 2025, with an ultimate completion date of September 24, 2025. This firm fixed-price, competitively awarded delivery order was placed without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract executed under...
- The Defense Logistics Agency awarded a delivery order valued at $8,116.87 to AmerisourceBergen Drug Corp for the supply of Imbruvica 140 mg capsules (90-count units) on April 22, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by May 13, 2025, with performance at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $48,701.22 to AmerisourceBergen Drug Corp for supply of Imbruvica 140 mg capsules (quantity: 90 units) with a completion date of October 10, 2025. This competitive award, issued on September 19, 2025, carries firm fixed pricing and contains no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Imbruvica 140 mg tablets (28-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by September 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count units) valued at $53,030.25 with a firm fixed price structure. The order is scheduled for completion by September 9, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a non-set-aside, competitively awarded contract and is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count) under a firm fixed-price contract on April 21, 2025. The contract carries a ceiling value of $15,151.52 and requires completion by May 12, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of pharmaceutical supply services to support federal medical procurement needs, with performance occurring at...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Imbruvica 420 mg tablets (28-count) with a ceiling value of $76,839.82. This firm fixed-price delivery order, with an ultimate completion date of September 9, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Imbruvica 420 mg tablets (28-count units) with a ceiling value of $16,932.55. This firm fixed price delivery order, which carries an ultimate completion date of June 3, 2025, represents a non-competitive set-aside contract and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical...
- The Defense Logistics Agency awarded a $8,116.87 delivery order to AmerisourceBergen Drug Corp for IMBRUVICA 140 mg capsules (90-count units) with a firm fixed price contract type. The award, issued on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a non-set-aside competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4PJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Imbruvica 140 mg capsules (90-count units) with a ceiling value of $24,350.61. This firm fixed-price delivery order, with an ultimate completion date of September 24, 2025, was competitively awarded without a set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary distribution operations for federal medical procurement. This delivery order represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen supplies critical medications and medical commodities to support Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The Imbruvica supply fulfills part of the company's comprehensive role as a pharmaceutical prime vendor within DLA's global supply chain, enabling delivery of specialty brand-name and generic medications across multiple therapeutic domains to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.4k | 9/3/25 |